Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04770389 · ClinicalTrials.gov registry record · Phase 2
Randomized Study of Obicetrapib in Combination With Ezetimibe
A Phase 2 study, sponsored by NewAmsterdam Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 112
- Enrollment target
NCT04770389 is a Phase 2 study that has completed, run by NewAmsterdam Pharma. The registered enrollment target is 112 participants.
The verdict
NCT04770389, a Phase 2 study, has completed, sponsored by NewAmsterdam Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 112 participants
- Enrollment target
Study Summary
This study will be a placebo-controlled, double-blind, randomized, phase 2 study in participants with mild dyslipidemia to evaluate the efficacy, safety, and tolerability of obicetrapib and ezetimibe combination therapy.
Interventions
- OTHER Placebo
- DRUG Ezetimibe 10mg
- DRUG Obicetrapib 5mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2021-02-23 |
| Est. Completion | 2021-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04770389
The ClinicalTrials.gov registry entry for NCT04770389 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NewAmsterdam Pharma, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04770389 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04770389 about?
NCT04770389 is a clinical study titled "Randomized Study of Obicetrapib in Combination With Ezetimibe". This study will be a placebo-controlled, double-blind, randomized, phase 2 study in participants with mild dyslipidemia to evaluate the efficacy, safety, and tolerability of obicetrapib and ezetimibe combination therapy.
What is the current status of trial NCT04770389?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 112 participants. The study started on 2021-02-23. Estimated completion is 2021-06-30.
What interventions are being tested in trial NCT04770389?
The interventions under investigation include: Placebo (OTHER), Ezetimibe 10mg (DRUG), Obicetrapib 5mg (DRUG).
Who is sponsoring clinical trial NCT04770389?
This trial is sponsored by NewAmsterdam Pharma, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.